INVVY - INVVY STOCK NEWS

Welcome to our dedicated page for INVVY news (Ticker: INVVY), a resource for investors and traders seeking the latest updates and insights on INVVY stock.

Indivior PLC (LSE/Nasdaq: INDV) is a global pharmaceutical company dedicated to developing medicines to treat substance use disorders (SUD) and serious mental illnesses. With a vision to provide evidence-based treatments for chronic conditions worldwide, Indivior is focused on transforming SUD into a recognized and treated chronic disease. Headquartered in Richmond, VA, Indivior's portfolio of products is available in 37 countries, with a pipeline of product candidates aiming to address various chronic conditions and co-occurring disorders of SUD.

05/23/2024 07:02 AM

News

Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance

Rhea-AI Summary

Indivior, a leading addiction treatment company, will host an analyst teach-in event in New York City, confirming its FY 2024 guidance. The company expects net revenue between $1,240m and $1,330m, an 18% increase from FY 2023. SUBLOCADE revenue is projected at $820m to $880m, a 35% rise. OPVEE revenue is anticipated to be $15m to $25m, and PERSERIS revenue is forecasted at $55m to $65m, a 43% increase. SUBOXONE Film market share is expected to decline by 1-2 percentage points. Adjusted gross margin is estimated to be in the low to mid-80s range.

Adjusted SG&A expenses are projected at $575m to $590m, with R&D expenses between $120m and $130m. Adjusted operating profit is expected to be $330m to $380m. The event will be webcast and aims to provide an in-depth overview of Indivior's growth and value creation strategies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.24%

Tags

04/25/2024 02:00 AM

News

Indivior Announces Q1 2024 Financial Results

Rhea-AI Summary

Indivior PLC (LSE/Nasdaq: INDV) has announced its Q1 2024 financial results, with the earnings release, investor presentation, and webcast available on their website. The live webcast presentation will be hosted by CEO Mark Crossley.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-8.29%

Tags

03/11/2024 02:43 PM

News

Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

Rhea-AI Summary

Indivior PLC announces successful results from a pharmacodynamic study showcasing OPVEE's rapid reversal of opioid-induced respiratory depression compared to intranasal naloxone. The study demonstrated OPVEE's efficacy in reversing respiratory depression to 95% of pre-opioid baseline within 5 minutes, outperforming naloxone. This comparison study highlights the urgent need for fast-acting reversal agents for synthetic opioids like fentanyl.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.99%

Tags

02/29/2024 02:02 AM

News

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

Rhea-AI Summary

Indivior PLC's subsidiary, Indivior Inc., receives final Court approval for a $385m settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation matter.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.15%

Tags

02/22/2024 02:00 AM

News

Indivior Announces Q4 / FY 2023 Financial Results

Rhea-AI Summary

Indivior PLC (INDV) released its financial results for the period ending December 31, 2023, with an earnings release, investor presentation, and webcast available on their website. CEO Mark Crossley will host a live webcast presentation at 13:00 BST. Participants can access the presentation online or telephonically.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

21.71%

Tags

11/09/2023 02:05 AM

News

Indivior Announces Q3 2023 Financial Results

Rhea-AI Summary

Indivior PLC (LSE/Nasdaq: INDV) announced its financial results for the period ending September 30, 2023. The earnings release, investor presentation, and webcast are available at indivior.com. The live webcast presentation will be hosted by CEO Mark Crossley at 13:00 BST. Details for access are provided.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5.47%

Tags

10/11/2023 04:20 PM

News

Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals

Rhea-AI Summary

Indivior gains exclusive global rights to develop ALA-1000, a three-month long-acting injectable treatment for opioid use disorder (OUD).

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.5%

Tags

09/26/2023 02:30 PM

News

Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada

Rhea-AI Summary

Rates of non-fatal overdose events were lower with SUBLOCADE treatment compared to other therapies, according to a study published in the Journal of Addiction Medicine. The study found that SUBLOCADE had a lower incidence rate of non-fatal opioid overdoses (1.7%) compared to sublingual buprenorphine/naloxone (19.3%) and methadone (46.8%), with statistically significant risk-adjusted differences of 6.5% and 8.6% respectively. The study also showed improvements in other clinical parameters. Further studies are needed to validate these findings.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.19%

Tags

08/21/2023 02:02 AM

News

Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims

Rhea-AI Summary

Indivior reaches agreement to resolve claims in Suboxone Antitrust Litigation, expects to pay $30 million to End Payor Claimants

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

6.05%

Tags

07/27/2023 02:00 AM

News

Indivior Announces Q2/H1 2023 Financial Results

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.65%

Tags

FAQ

What is the market cap of INVVY (INVVY)?

The market cap of INVVY (INVVY) is approximately 3.0B.

What does Indivior PLC specialize in?

Indivior PLC specializes in developing medicines to treat substance use disorders (SUD) and serious mental illnesses.

Where is Indivior PLC headquartered?

Indivior PLC is headquartered in Richmond, VA, United States.

How many countries is Indivior's portfolio of products available in?

Indivior's portfolio of products is available in 37 countries worldwide.

What is Indivior's vision for patients around the world?

Indivior's vision is to provide all patients with access to evidence-based treatment for chronic conditions and co-occurring disorders of SUD.

What is the focus of Indivior's global portfolio?

Indivior's global portfolio focuses on opioid use disorder treatments and has a pipeline of product candidates to address various chronic conditions and co-occurring disorders of SUD.